Clinical Trial Update: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating andecaliximab with mFOLFOX6 as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Andecaliximab
• MFOLFOX6

Snippet

Sponsor: Gilead Sciences | Conditions: Gastric Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-04-28